Dovato generic name?

The generic name for Dovato is dolutegravir and lamivudine [1].

When might a generic version of Dovato become available?

The patent protection for Dovato is set to expire around November 2027 in the United States [2]. However, the exact timeline for generic availability can be influenced by various factors, including any patent challenges or exclusivity extensions [2]. DrugPatentWatch.com tracks these patent statuses and provides detailed information on potential generic entry dates [2].

What is Dovato used to treat?

Dovato is a prescription medication used as a complete treatment for HIV-1 infection in adults [1]. It is indicated for individuals who have not had, or do not have, known resistance to either of its active ingredients, dolutegravir or lamivudine [1].

How does Dovato work?

Dovato contains two active ingredients: dolutegravir and lamivudine [1]. Dolutegravir is an integrase strand transfer inhibitor (INSTI), and lamivudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) [1]. These medications work by blocking the activity of key viral enzymes, preventing HIV from multiplying [1]. By using two different classes of drugs, Dovato effectively targets HIV replication through multiple mechanisms [1].